PK/ADA Bioanalytical Assay Development Using Research Biosimilar Reference Standards

Pharmacokinetic (PK) and anti-drug antibody (ADA) assays are mandatory components of biopharmaceutical development. Every therapeutic antibody entering clinical trials requires validated bioanalytical methods to measure drug concentration (PK) and immunogenicity (ADA) in patient samples. For background on what research biosimilars are and how they differ from originator drugs, see our Research Biosimilar and Biosimilar vs. Originator guides.

Practical Guide

PK assay principle: a sandwich ELISA captures the therapeutic antibody (drug) from serum using an anti-idiotype antibody or the target antigen, then detects it with a labeled secondary reagent. Research biosimilar antibodies serve as calibration standards and QC samples, spiked at known concentrations to generate the standard curve.

ADA assay principle: the bridging ELISA format uses the drug molecule itself to capture and detect ADAs. The drug is coated on the plate (or conjugated to beads) and simultaneously used as a labeled detection reagent. Research biosimilar drug molecules provide the essential reagent for both capture and detection arms.

Key considerations: research biosimilar reference standards must match the therapeutic antibody in binding specificity (same variable region sequence) and ideally in isotype (same Fc). As recombinant antibodies, they offer batch-to-batch consistency critical for assay reproducibility. Minor glycosylation differences between research-grade and GMP-grade drug product are generally acceptable for assay development and validation, but formal qualification against a GMP reference standard is required for regulated studies. Binding kinetics can be confirmed by SPR or BLI.

abinScience offers 2,700+ research biosimilar antibodies covering approved and clinical-stage therapeutics across immuno-oncology (anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-HER2), autoimmune (anti-TNF-α, anti-IL-6R, anti-IL-17A), and hematology (anti-CD20, anti-CD38, anti-BCMA).

For PK/ADA ELISA development, consider pairing the biosimilar drug molecule with: recombinant target protein (as capture antigen — see our Recombinant Protein Handling Guide for reconstitution best practices), anti-human IgG Fc secondary antibodies (for detection), and anti-idiotype antibodies (for drug-specific capture in multiplex settings). For a complete oncology reagent overview, visit our Cancer Research Reagents hub.

References

1. Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides. AAPS J. 2014;16(4):658-673. doi: 10.1208/s12248-014-9599-2

2. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi: 10.1126/science.aaa8172

3. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

All products are for research use only. For technical support, contact order@abinscience.com.